Literature DB >> 30169876

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

Nicole A P Lieberman1, Kole DeGolier1, Heather M Kovar1, Amira Davis1, Virginia Hoglund1, Jeffrey Stevens2, Conrad Winter3, Gail Deutsch4, Scott N Furlan1, Nicholas A Vitanza5, Sarah E S Leary5, Courtney A Crane1,6.   

Abstract

Background: Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG cannot be surgically resected. Immunotherapy has the ability to target tumor cells specifically; however, little is known about the tumor microenvironment in DIPGs. We sought to characterize infiltrating immune cells and immunosuppressive factor expression in pediatric low- and high-grade gliomas and DIPG.
Methods: Tumor microarrays were stained for infiltrating immune cells. RNA was isolated from snap-frozen tumor tissue and Nanostring analysis performed. DIPG and glioblastoma cells were co-cultured with healthy donor macrophages, T cells, or natural killer (NK) cells, and flow cytometry and cytotoxicity assays performed to characterize the phenotype and function, respectively, of the immune cells.
Results: DIPG tumors do not have increased macrophage or T-cell infiltration relative to nontumor control, nor do they overexpress immunosuppressive factors such as programmed death ligand 1 and/or transforming growth factor β1. H3.3-K27M DIPG cells do not repolarize macrophages, but are not effectively targeted by activated allogeneic T cells. NK cells lysed all DIPG cultures. Conclusions: DIPG tumors have neither a highly immunosuppressive nor inflammatory microenvironment. Therefore, major considerations for the development of immunotherapy will be the recruitment, activation, and retention of tumor-specific effector immune cells.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30169876      PMCID: PMC6303470          DOI: 10.1093/neuonc/noy145

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  38 in total

Review 1.  Macrophage Polarization.

Authors:  Peter J Murray
Journal:  Annu Rev Physiol       Date:  2016-10-21       Impact factor: 19.318

2.  Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.

Authors:  Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-01       Impact factor: 11.205

3.  Characterization of distinct immunophenotypes across pediatric brain tumor types.

Authors:  Andrea M Griesinger; Diane K Birks; Andrew M Donson; Vladimir Amani; Lindsey M Hoffman; Allen Waziri; Michael Wang; Michael H Handler; Nicholas K Foreman
Journal:  J Immunol       Date:  2013-09-27       Impact factor: 5.422

4.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Authors:  Courtney A Crane; Seunggu J Han; Jeffery J Barry; Brian J Ahn; Lewis L Lanier; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2009-11-05       Impact factor: 12.300

5.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

Authors:  Jennifer C Rodrigues; Guido C Gonzalez; Lei Zhang; George Ibrahim; John J Kelly; Michael P Gustafson; Yi Lin; Allan B Dietz; Peter A Forsyth; V Wee Yong; Ian F Parney
Journal:  Neuro Oncol       Date:  2009-12-22       Impact factor: 12.300

6.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

Review 7.  Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy.

Authors:  Kara W Moyes; Nicole A P Lieberman; Shannon A Kreuser; Harrison Chinn; Conrad Winter; Gail Deutsch; Virginia Hoglund; Reid Watson; Courtney A Crane
Journal:  Hum Gene Ther       Date:  2016-10-18       Impact factor: 5.695

8.  Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.

Authors:  Ashley S Plant; Shohei Koyama; Claire Sinai; Isaac H Solomon; Gabriel K Griffin; Keith L Ligon; Pratiti Bandopadhayay; Rebecca Betensky; Ryan Emerson; Glenn Dranoff; Mark W Kieran; Jerome Ritz
Journal:  J Neurooncol       Date:  2018-01-10       Impact factor: 4.130

9.  VEGF may contribute to macrophage recruitment and M2 polarization in the decidua.

Authors:  Karen C Wheeler; Manoj K Jena; Bhola S Pradhan; Neha Nayak; Subhendu Das; Chaur-Dong Hsu; David S Wheeler; Kang Chen; Nihar R Nayak
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

10.  An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells.

Authors:  Nicole A P Lieberman; Kole DeGolier; Kristen Haberthur; Harrison Chinn; Kara W Moyes; Myriam N Bouchlaka; Kirsti L Walker; Christian M Capitini; Courtney A Crane
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

View more
  44 in total

1.  Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.

Authors:  Cavan P Bailey; Mary Figueroa; Achintyan Gangadharan; Yanwen Yang; Megan M Romero; Bridget A Kennis; Sridevi Yadavilli; Verlene Henry; Tiara Collier; Michelle Monje; Dean A Lee; Linghua Wang; Javad Nazarian; Vidya Gopalakrishnan; Wafik Zaky; Oren J Becher; Joya Chandra
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 2.  Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.

Authors:  Razina Aziz-Bose; Michelle Monje
Journal:  Curr Opin Oncol       Date:  2019-11       Impact factor: 3.645

Review 3.  Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.

Authors:  Kyle Wierzbicki; Karthik Ravi; Andrea Franson; Amy Bruzek; Evan Cantor; Micah Harris; Morgan J Homan; Bernard L Marini; Abed Rahman Kawakibi; Ramya Ravindran; Rodrigo Teodoro; Viveka Nand Yadav; Carl Koschmann
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

4.  Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.

Authors:  James L Ross; Zhihong Chen; Cameron J Herting; Yura Grabovska; Frank Szulzewsky; Montserrat Puigdelloses; Lenore Monterroza; Jeffrey Switchenko; Nitin R Wadhwani; Patrick J Cimino; Alan Mackay; Chris Jones; Renee D Read; Tobey J MacDonald; Matthew Schniederjan; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

Review 5.  Pineal Gland Tumor Microenvironment.

Authors:  Joham Choque-Velasquez; Szymon Baluszek; Roberto Colasanti; Sajjad Muhammad; Juha Hernesniemi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas.

Authors:  Lai-Rong Song; Jian-Cong Weng; Cheng-Bei Li; Xu-Lei Huo; Huan Li; Shu-Yu Hao; Zhen Wu; Liang Wang; Da Li; Jun-Ting Zhang
Journal:  JCI Insight       Date:  2020-03-31

Review 7.  Immunotherapy for pediatric brain tumors: past and present.

Authors:  Jessica B Foster; Peter J Madsen; Meenakshi Hegde; Nabil Ahmed; Kristina A Cole; John M Maris; Adam C Resnick; Phillip B Storm; Angela J Waanders
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

8.  Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.

Authors:  Flor Mendez; Padma Kadiyala; Felipe J Nunez; Stephen Carney; Fernando M Nunez; Jessica C Gauss; Ramya Ravindran; Sheeba Pawar; Marta Edwards; Maria Belen Garcia-Fabiani; Santiago Haase; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2020-04-24       Impact factor: 12.531

Review 9.  Immune profiling of pediatric solid tumors.

Authors:  Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

10.  Considerations when treating high-grade pediatric glioma patients with immunotherapy.

Authors:  Erin Crotty; Kira Downey; Lauren Ferrerosa; Catherine Flores; Bindu Hegde; Scott Raskin; Eugene Hwang; Nicholas Vitanza; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2020-12-17       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.